Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Area of Science:

• Pharmacology and Toxicology
• Infectious Diseases
• Clinical Trials

Background:

• Tuberculosis (TB) chemotherapy toxicity requires better characterization.
• The REMoxTB trial data offers insights into risks of standard and moxifloxacin-containing regimens.

Purpose of the Study:

• To assess the incidence and severity of adverse events (AEs) in TB chemotherapy.
• To compare toxicity profiles of standard versus experimental moxifloxacin-based TB treatment regimens.

Main Methods:

• Analysis of grade 3 & 4 AEs from the REMoxTB clinical trial.
• Logistic regression models to identify risk factors for AEs and their association with treatment outcomes.
• Timing of AEs during intensive and continuation phases of therapy was analyzed.

Main Results:

• Standard therapy had 113 related AEs; experimental arms had fewer (63 & 65).
• Female gender and HIV-positive status were associated with higher AE risk on standard therapy.
• Patients experiencing AEs were more likely to fail treatment or relapse (adjOR 3.11).

Conclusions:

• Experimental moxifloxacin regimens demonstrated lower toxicity compared to standard TB therapy.
• Female and HIV-positive patients face higher risks of AEs with standard TB treatment.
• Targeted monitoring of patients with AEs could improve TB treatment outcomes.